Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?

被引：54

作者：

Clark, GM ^{[1
]}

机构：

[1] Univ Texas, Hlth Sci Ctr, Div Med Oncol, San Antonio, TX 78284 USA

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1998年 / 90卷 / 18期

关键词：

D O I：

10.1093/jnci/90.18.1320

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：1320 / 1321

页数：2

共 10 条

[1]

HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA [J].

ALLRED, DC ;

CLARK, GM ;

TANDON, AK ;

MOLINA, R ;

TORMEY, DC ;

OSBORNE, CK ;

GILCHRIST, KW ;

MANSOUR, EG ;

ABELOFF, M ;

EUDEY, L ;

MCGUIRE, WL .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :599-605

[2]

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer [J].

Budman, DR ;

Berry, DA ;

Cirrincione, CT ;

Henderson, IC ;

Wood, WC ;

Weiss, RB ;

Ferree, CR ;

Muss, HB ;

Green, MR ;

Norton, L ;

Frei, E .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (16) :1205-1211

[3]

PROGNOSTIC IMPORTANCE OF C-ERBB-2 EXPRESSION IN BREAST-CANCER [J].

GUSTERSON, BA ;

GELBER, RD ;

GOLDHIRSCH, A ;

PRICE, KN ;

SAVESODERBORGH, J ;

ANBAZHAGAN, R ;

STYLES, J ;

RUDENSTAM, CM ;

GOLOUH, R ;

REED, R ;

MARTINEZTELLO, F ;

TILTMAN, A ;

TORHORST, J ;

GRIGOLATO, P ;

BETTELHEIM, R ;

NEVILLE, AM ;

BURKI, K ;

CASTIGLIONE, M ;

COLLINS, J ;

LINDTNER, J ;

SENN, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1049-1056

[4]

Jarvinen TAH, 1996, AM J PATHOL, V148, P2073

[5]

C-ERBB-2 EXPRESSION AND RESPONSE TO ADJUVANT THERAPY IN WOMEN WITH NODE-POSITIVE EARLY BREAST-CANCER [J].

MUSS, HB ;

THOR, AD ;

BERRY, DA ;

KUTE, T ;

LIU, ET ;

KOERNER, F ;

CIRRINCIONE, CT ;

BUDMAN, DR ;

WOOD, WC ;

BARCOS, M ;

HENDERSON, IC .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (18) :1260-1266

[6]

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer [J].

Paik, SM ;

Bryant, J ;

Park, CH ;

Fisher, B ;

Tan-Chiu, E ;

Hyams, D ;

Fisher, ER ;

Lippman, ME ;

Wickerham, DL ;

Wolmark, N .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1361-1370

[7]

SAMPLE-SIZE REQUIREMENTS AND LENGTH OF STUDY FOR TESTING INTERACTION IN A 2 X K FACTORIAL DESIGN WHEN TIME-TO-FAILURE IS THE OUTCOME [J].

PETERSON, B ;

GEORGE, SL .

CONTROLLED CLINICAL TRIALS, 1993, 14 (06) :511-522

[8]

RAVDIN PM, 1998, P AN M AM SOC CLIN, V17, pA97

[9]

HUMAN-BREAST CANCER - CORRELATION OF RELAPSE AND SURVIVAL WITH AMPLIFICATION OF THE HER-2 NEU ONCOGENE [J].

SLAMON, DJ ;

CLARK, GM ;

WONG, SG ;

LEVIN, WJ ;

ULLRICH, A ;

MCGUIRE, WL .

SCIENCE, 1987, 235 (4785) :177-182

[10]

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer [J].

Thor, AD ;

Berry, DA ;

Budman, DR ;

Muss, HB ;

Kute, T ;

Henderson, IC ;

Barcos, M ;

Cirrincione, C ;

Edgerton, S ;

Allred, C ;

Norton, L ;

Liu, ET .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1346-1360

← 1 →